Back to top
more

National Vision (EYE)

(Delayed Data from NSDQ)

$13.61 USD

13.61
2,205,953

+0.41 (3.11%)

Updated Aug 5, 2024 04:00 PM ET

After-Market: $13.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Medtronic Acquires Klue to Strengthen Diabetes Management Arm

by Zacks Equity Research

Medtronic (MDT) strengthens its diabetes business through the Klue acquisition and subsequent development of its PCL technology.

Globus Medical Rides on New Product Menu, U.S. Spine Business

by Zacks Equity Research

Globus Medical's (GMED) U.S. Spine business is securing a market share on the back of competitive representative recruiting and an implant pull-through from ExcelsiusGPS installations.

Boston Scientific Hits New 52-Week High: What's Driving it?

by Zacks Equity Research

Boston Scientific (BSX) is optimistic about sustaining the growth momentum on recent positive developments.

Boston Scientific's First Single-Use Duodenoscope Gets FDA Nod

by Zacks Equity Research

Boston Scientific's (BSX) EXALT Model D single-use duodenoscope gets clearance from the FDA for use in ERCP procedures.

Bruker Launches Luxendo TruLive3D Imager, Expands NANO Arm (Revised)

by Zacks Equity Research

Bruker's (BRKR) latest Luxendo TruLive3D Imager revolutionizes cell culture live imaging in natural environments.

CVS Health Rides on Aetna Prospects, Strong Selling Season

by Zacks Equity Research

CVS Health's (CVS) 2020 PBM selling season is approaching closure and the 2021 selling season is ongoing.

Omnicell-Huron Sign a Pact for Outcome-Based Expert Services

by Zacks Equity Research

Omnicell (OMCL) partners Huron to provide customers with committed expertise.

Bruker Launches Luxendo TruLive3D Imager in Mass Spectrometry

by Zacks Equity Research

Bruker's (BRKR) Luxendo TruLive3D Imager revolutionizes cell culture live imaging in natural environment.

Globus Medical Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Globus Medical (GMED) is optimistic about sustaining its growth momentum on recent positive developments.

NuVasive Hits New 52-Week High: What's Driving the Stock?

by Zacks Equity Research

NuVasive (NUVA) is optimistic about maintaining the momentum on several positive developments.

TransMedics' OCS Technology Sees Success in Heart Transplant

by Zacks Equity Research

TransMedics (TMDX) successfully completes heart transplants from DCD donors, using its OCS technology.

National Vision (EYE) Up 3.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Omnicell to Feature Upgrades in Medication Management at ASHP

by Zacks Equity Research

Omnicell (OMCL) to showcase innovations in medication management solution portfolio to minimize human errors by care providers.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for December 6th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

Myriad Genetics Reports Favorable Study Result on Prequel

by Zacks Equity Research

Myriad Genetics (MYGN) posts breakthrough results on Prequel Prenatal Screen methodology, proving its superiority over traditional methods.

NuVasive Advances on Global Footprint Despite Pricing Woes

by Zacks Equity Research

Within NuVasive's (NUVA) U.S. Spinal Hardware business, a strong uptick in case volume and tangible growth in the XLIF and ALIF franchises are major upsides.

Haemonetics (HAE) Launches SafeTrace Tx in North America

by Zacks Equity Research

Haemonetics (HAE) expands the transfusion management portfolio with SafeTrace Tx, the latest in its transfusion management software product line.

Urmimala Biswas headshot

Thermo Fisher Rides on New Product Suite and Global Growth

by Urmimala Biswas

A series of product launches with better precision medicine initiatives aids Thermo Fisher's (TMO) performance.

    EYE or NEOG: Which Is the Better Value Stock Right Now?

    by Zacks Equity Research

    EYE vs. NEOG: Which Stock Is the Better Value Option?

    ViewRay Allies With Two Majors in MR-Guided Radiation Therapy

    by Zacks Equity Research

    ViewRay's (VRAY) collective investments from Elekta and Medtronic are conditioned to the consummation of an equity capital hike of at least $75 million.

      RadNet Hits New 52-Week High: What's Driving the Stock?

      by Zacks Equity Research

      RadNet (RDNT) is optimistic about maintaining momentum on several positive developments.

      Hologic (HOLX) to Showcase Health Solutions Portfolio at RSNA

      by Zacks Equity Research

      Hologic (HOLX) to highlight its latest offerings in its breast health portfolio at the ongoing annual RSNA meet.

      BioSig Technologies Partners Mayo Clinic to Treat Arrhythmia

      by Zacks Equity Research

      BioSig Technologies (BSGM) signs agreement with Mayo Foundation for improving arrhythmia treatment along with covering therapies for autonomic nervous system disease.

      Here's Why You Should Invest in ResMed (RMD) Stock Right Now

      by Zacks Equity Research

      Investors continue to be optimistic about ResMed (RMD) on its stellar performance.

      National Vision Holdings, Inc. (EYE) Shares March Higher, Can It Continue?

      by Zacks Equity Research

      As of late, it has definitely been a great time to be an investor in National Vision Holdings, Inc. (EYE).